glp 1 post partum GLP-1 agonists are showing up more often in our pelvic health caseloads — pre-conception, postpartum, and across the lifespan. What we do know: • Higher BMI is a risk factor for pelvic From JAMA: Postpartum prescription of

But the real GLP-1 story appears to be just getting started

No pharmacotherapy is approved for the treatment of NAFLD and, currently, the cornerstone treatment is lifestyle modifications focusing on bodyweight loss, notoriously difficult to obtain and even more difficult to maintain

They reduce de novo lipogenesis by inhibiting transcription factor sterol regulatory element-binding protein 1c (SREBP-1c), which is a master regulator of fatty acid synthesis (Shantaram et al., 2025

Increasing the endogenous secretion of GLP-1 The apical surface of L-cells in the intestinal lining plays a critical role in sensing luminal compounds such as carbohydrates, proteins, gut microbiota, bacteria-derived molecules, bile acids, lipids, fatty acids, and polyphenols

Although GLP-1 receptor agonists are mostly intended to be diabetes drugs, they are now being used not just for managing blood sugar but also for treating obesity and aiding in long-term weight management